Delayed On-Demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported by Italian Patients

Stefania Nicola¹, Andrea Zanichelli², Pietro Accardo³, Francesco Arcoleo³, Donatella Bignardi⁴, Caterina Colangelo⁵, Francesco Giardino⁶, Antonio Gidaro⁷, Marica Giliberti⁸, Maria Domenica Guarino⁹, Paola Lucia Minciullo¹⁰, Francesca Perego¹¹, Riccardo Senter¹, Giuseppe Spadaro¹², Paola Triggianese¹³, Massimo Triggiani¹⁴, Sherry Danese¹⁵, Julie Ulloa¹⁵, Vibha Desai¹⁶, Tomas Andriotti¹⁶, Paul Audhya¹⁶, Mauro Cancian¹⁷


¹Allergy and Immunology Unit - AO Ordine Mauriziano di Torino and Department of Medical Sciences - University of Turin, Italy; ²Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; ³A.O. "Ospedali Riuniti Villa Sofia-Cervello" – Presidio Ospedaliero Cervello, Palermo, Italy; ⁴IRCCS Ospedale Policlinico San Martino Genova, Genova, Italy; ⁴IRCCS Ospedale Policlinico San Martino Genova, Italy; ⁴IRCCS Ospedale Policlinico San Marti Sacco, Università degli Studi di Milano, Milano, Italy; ⁸Azienda Ospedaliero-Universitaria "Policlinico" di Bari, Bari, Italy; ⁹Presidio Ospedaliero di Civitanova Marche, Italy; ¹¹IRCCS Istituti Clinici Scientifici Maugeri, Milano, Italy; ¹²Azienda Ospedaliera Universitaria Federico II di Napoli, Italy; ¹³Azienda Ospedaliera Universitaria, Salerno, Italy; ¹⁴Azienda Ospedaliera Universitaria, Salerno, Italy; ¹⁴Azienda Ospedaliera Universitaria, Roma, Italy; ¹⁴Azienda Ospedaliera Universitaria, Salerno, Italy; ¹⁴Azienda Ospedaliera Universitaria, Salerno, Italy; ¹⁵Outcomes Insights, Agoura Hills, CA, United States; ¹⁶KalVista Pharmaceuticals, Cambridge, MA, United States; ¹⁷Azienda Ospedaliera, Università degli Studi di Padova, Padova, Italy;

Background

- Hereditary angioedema (HAE) is characterized by unpredictable swelling attacks affecting mucosal and subcutaneous tissues, which are typically painful, debilitating, and potentially fatal
- WAO/EAACI guidelines recommend the early use of ondemand treatment following recognition of an HAE attack to reduce morbidity and prevent mortality¹⁻³
- Despite the recommendation for early treatment, recent research suggests that patients delay on-demand treatment of their attacks⁴

Obiective

To assess the patient's time to treatment of their last attack along with identifying barriers contributing to treatment delay



Methods

- Individuals with Type 1 or 2 HAE due to C1 inhibitor deficiency were recruited through the Italian Network for Hereditary and Acquired Angioedema (ITACA) between September 2023 and January 2024
- Respondents enrolled were ≥12 years old and had to have treated with an approved on-demand therapy ≥1 HAE attack within 3 months prior to the survey
- The survey was self-reported, and took respondents approximately 20 minutes to complete

Results

Table 1. Respondent Characteristics


	Total (n=56)	On-Demand Only (n=25)	On-Demand + LTP (n=31)	Adults (n=48)	Adolescents (n=8)
Current age (years; mean)	41	41	40	45	15
Age of diagnosis (years; mean)	17	21	14	19	8
<u>Gender</u> Male Female	23 (41%) 33 (59%)	10 (40%) 15 (60%)	13 (42%) 18 (58%)	18 (38%) 30 (63%)	5 (63%) 3 (38%)

Mean (SD) (nour)	2.8 (2.4)	2.5 (2.5)	3.0 (2.4)	2.7 (2.3)	2.9 (2.3)
Median (1Q, 3Q)	2.0 (1.0, 4.0)	2.0 (1.0, 3.0)	3.0 (1.0, 4.0)	2.0 (1.0, 3.5)	2.5 (0.9, 5.0)
Min-Max	0-12	0-12	0-10	0-12	0-6

Note: Values less than 5 percent are not labeled

Q33. After you first noticed the start of the attack, how much time passed until you treated the attack with on-demand treatment?

- The median time to treatment was 2 hours (interquartile range: 1-4) overall, but 3 hours for those receiving LTP and 2.5 hours for adolescents
- Only 11% of respondents (6/56) treated their attack in <1 hour



Note: Values less than 5 percent are not labeled

Q31a. When the attack was at its most severe, how would you describe it?

Peak attack severity increased with time to initial treatment

Figure 4. Peak Attack Severity by Time to Initial Treatment

<u>HAE Type</u> Type I	51 (91%)	24 (96%)	27 (87%)	44 (92%)	7 (88%)
Type II	5 (9%)	1 (4%)	4 (13%)	4 (8%)	1 (13%)

This interim analysis included 56 respondents, including 48 adults and 8 adolescents (<18 years)

Figure 1. First On-Demand Treatment for Last Treated Attack

• 55% were receiving long-term prophylaxis (LTP) at the time of their most recent treated HAE attack

	Treatment Used (n=56)	On- Demand Only (n=25)	On- Demand + LTP (n=31)	Adults (n=48)	Adolesc ents (n=8)
Icatibant (Firazyr and generic)	55%	44%	65%	63%	13%
Plasma derived C1 esterase inhibitor (Berinert)	43%	56%	32%	35%	88%
Plasma derived C1 esterase inhibitor (Cinryze)	2%		3%	2%	
Recombinant C1 esterase inhibitor (Ruconest)	0%				

Most adults used icatibant for on-demand treatment for their last attack while most adolescents used plasma derived C1 esterase inhibitor

Figure 2. Perception of Time to Treatment as "Early"

"I Treated the Attack Early"


- Only 33% of those who treated their attacks in less than 1 hour described their attack at peak as severe or very severe
- 40%, 39%, 75%, and 100% of those who treated within 1 to <2 hours, 2 to <5 hours, 5 to <8 hours, and 8 or more hours, respectively, reported the peak of their attack as severe or very severe

Figure 5. Barriers to Treating HAE Attack Sooner

Barriers (Detailed) (Excluding those who treated the attack immediately; ranked top 5; n=45)			<u>Ranked Top 5</u>	
		Adults (n=40)	Adolescents (n=5)	
I was not certain it was a real / actual attack	44%	40%	80%	
I thought the attack would be mild	40%	43%	20%	
I wanted to save my on-demand treatment for a severe attack	27%	28%	20%	
I waited to treat until the attack was severe	24%	23%	40%	
I did not want to / could not interrupt what I was doing	18%	18%	20%	
I did not have anyone to help me	11%	10%	20%	
I did not have my on-demand treatment with me	9%	8%	20%	
I did not have a private place to administer treatment	7%	5%	20%	
I had to go to the hospital / emergency center for treatment	4%	5%		
I wanted to avoid the burning, stinging or pain with the injection	4%	5%	_	
I wanted to avoid the side effects of treatment	4%	5%	_	
I wanted to avoid the pain of the needle	2%	3%	_	
I did not feel well enough to prepare and administer the treatment	2%	3%	_	
My on-demand treatment was expensive	2%	3%	_	

Q35. What prevented you from treating this HAE attack sooner with on-demand treatment? (Top 5 in order of importance)

- Forty-five respondents (80%) who reported that they did not treat their most recent attack immediately were asked to rank their top 5 reasons for not treating earlier
- Uncertainty that the attack was real (44%), thinking the attack was mild (40%), and wanting to save on-demand treatment (27%) were the most common barriers; treatment-related barriers included not wanting to interrupt what they were doing (18%), not having anyone to help (11%), and not having a private place to administer treatment (7%)



 73% of respondents (41/56) believed they treated their attack early, despite only 15% of those respondents treating in less than one hour The mean time to treatment for those who believed they treated early was 2.2 hours

Conclusions

- Many respondents did not meet guideline recommendations for prompt on-demand treatment following HAE attack onset
- Those who delayed treatment were more likely to have severe/very severe attacks
- Uncertainty that the attack was real and thinking the attack was going to stay mild were the most common barriers to treating earlier
- Treatment related barriers included not wanting to interrupt what they were doing, not having anyone to help, and not having a private place to administer treatment
- These findings highlight a need to proactively address barriers contributing to treatment delays, including a need for oral on-demand treatment options, especially among adolescents

Disclosures

This study was funded by KalVista Pharmaceuticals.

References

1. Betschel S et al. Allergy, Asthma & Clinical Immunology. 2019/11/25 2019;15(1):72.; 2. Busse PJ et al. J Allergy Clin Immunol Pract. Jan 2021;9(1):132-150.e3.; 3. Maurer M et al. Allergy. Jul 2022;77(7):1961-1990.; 4. Radojicic C et al. J Allergy Clini Immunol, 151 (2): AB143

Presented: 2024 National Congress of the Italian Society of Allergy, Asthma and Clinical Immunology, October 4 & 5, 2024 in Rome, Italy.



To view this poster after the presentation, visit KalVista Virtual Medical Booth